These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 5232235)

  • 21. US consumer group criticizes proposal to allow drug makers to challenge safety information.
    McCarthy M
    BMJ; 2015 Mar; 350():h1514. PubMed ID: 25784706
    [No Abstract]   [Full Text] [Related]  

  • 22. The marketing of a drug.
    Wolfe SM
    Health Med; 1982; 1(2):31-2. PubMed ID: 10257087
    [No Abstract]   [Full Text] [Related]  

  • 23. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
    Cheng CM; Shin J; Guglielmo BJ
    JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
    [No Abstract]   [Full Text] [Related]  

  • 24. When does compounding become manufacturing?
    Gushee J
    J Am Vet Med Assoc; 1994 Jul; 205(2):235-6. PubMed ID: 7928585
    [No Abstract]   [Full Text] [Related]  

  • 25. Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives.
    Cutler NR; Sramek JJ; Greenblatt DJ; Chaikin P; Ford N; Lesko LJ; Davis B; Williams RL
    J Clin Pharmacol; 1997 Sep; 37(9):767-83. PubMed ID: 9549630
    [No Abstract]   [Full Text] [Related]  

  • 26. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety.
    Qato DM; Alexander GC
    JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of pediatric drug formulations.
    Nahata MC
    Pediatrics; 1999 Sep; 104(3 Pt 2):607-9. PubMed ID: 10469800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restoring confidence in the pharmaceutical industry.
    Bauchner H; Fontanarosa PB
    JAMA; 2013 Feb; 309(6):607-9. PubMed ID: 23403686
    [No Abstract]   [Full Text] [Related]  

  • 29. U.S. Food and Drug Administration Takes Aim (Again) at Animal Compounding: Draft Guidance for Industry #256 Lacks Authority, Will Increase Costs, and Put Pets at Risk.
    Brunner S
    Int J Pharm Compd; 2020; 24(3):198-199. PubMed ID: 32401738
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials.
    Mitka M
    JAMA; 2012 Jun; 307(24):2576-7. PubMed ID: 22735406
    [No Abstract]   [Full Text] [Related]  

  • 31. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1992 Mar; 267(11):1442. PubMed ID: 1538524
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug discovery-background and foreground.
    Tishler M
    Clin Pharmacol Ther; 1973; 14(4):479-86. PubMed ID: 4723254
    [No Abstract]   [Full Text] [Related]  

  • 33. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 34. [Abuse-related adverse drug reactions and abuse deterrent formulations].
    Papaseit E; Pérez-Mañá C; Torrens M; Farré M
    Med Clin (Barc); 2013 Nov; 141(10):454-8. PubMed ID: 24144061
    [No Abstract]   [Full Text] [Related]  

  • 35. Science, drugs, and the Food and Drug Administration.
    De Haen P
    N Y State J Med; 1971 Jul; 71(13):1644-50. PubMed ID: 5284708
    [No Abstract]   [Full Text] [Related]  

  • 36. Program seeks to enlist physicians to flag questionable promotion of drugs.
    Mitka M
    JAMA; 2010 Jul; 304(1):28-9. PubMed ID: 20606140
    [No Abstract]   [Full Text] [Related]  

  • 37. The FDA Safety and Innovation Act.
    Steinbrook R; Sharfstein JM
    JAMA; 2012 Oct; 308(14):1437-8. PubMed ID: 23047356
    [No Abstract]   [Full Text] [Related]  

  • 38. Role of the FDA in Affordability of Off-Patent Pharmaceuticals.
    Greene JA; Anderson G; Sharfstein JM
    JAMA; 2016 Feb; 315(5):461-2. PubMed ID: 26747694
    [No Abstract]   [Full Text] [Related]  

  • 39. One method for the systematic evaluation of adverse drug experience data within a pharmaceutical firm.
    Westlin WF; Cuddihy RV; Bursik RJ; Seifert BG; Koelle JG
    Methods Inf Med; 1977 Oct; 16(4):240-70. PubMed ID: 927209
    [No Abstract]   [Full Text] [Related]  

  • 40. 'Extreme duplication' in the US FDA Adverse Events Reporting System database.
    Hauben M; Reich L; DeMicco J; Kim K
    Drug Saf; 2007; 30(6):551-4. PubMed ID: 17536881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.